Literature DB >> 30940906

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.

Antonin Papin1,2,3, Benoit Tessoulin1,3,4, Céline Bellanger1,2,3, Anne Moreau3,5, Yannick Le Bris1,3,6, Hervé Maisonneuve3,7, Philippe Moreau1,3,4, Cyrille Touzeau1,3,4, Martine Amiot1,2,3, Catherine Pellat-Deceunynck1,2,3, Steven Le Gouill1,3,4, David Chiron8,9,10.   

Abstract

The microenvironment strongly influences mantle cell lymphoma (MCL) survival, proliferation, and chemoresistance. However, little is known regarding the molecular characterization of lymphoma niches. Here, we focused on the interplay between MCL cells and the associated monocytes/macrophages. Using circulating MCL cells (n = 58), we showed that, through the secretion of CSF1 and, to a lesser extent, IL-10, MCL polarized monocytes into specific CD163+ M2-like macrophages (MϕMCL). In turn, MϕMCL favored lymphoma survival and proliferation ex vivo. We next demonstrated that BTK inhibition abrogated CSF1 and IL-10 production in MCL cells, leading to the inhibition of macrophage polarization and consequently resulting in the suppression of microenvironment-dependent MCL expansion. In vivo, we showed that CSF1 and IL-10 plasma concentrations were higher in MCL patients than in healthy donors, and that monocytes from MCL patients overexpressed CD163. Further analyses of serial samples from ibrutinib-treated patients (n = 8) highlighted a rapid decrease of CSF1, IL-10, and CD163 in responsive patients. Finally, we showed that targeting the CSF1R abrogated MϕMCL-dependent MCL survival, irrespective of their sensitivity to ibrutinib. These data reinforced the role of the microenvironment in lymphoma and suggested that macrophages are a potential target for developing novel therapeutic strategies in MCL.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30940906     DOI: 10.1038/s41375-019-0463-3

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

Review 1.  Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.

Authors:  Khalil Saleh; Morgane Cheminant; David Chiron; Barbara Burroni; Vincent Ribrag; Clémentine Sarkozy
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

2.  Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma.

Authors:  Tiziana Annese; Giuseppe Ingravallo; Roberto Tamma; Michelina De Giorgis; Eugenio Maiorano; Tommasina Perrone; Francesco Albano; Giorgina Specchia; Domenico Ribatti
Journal:  Transl Oncol       Date:  2020-02-29       Impact factor: 4.243

3.  Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.

Authors:  Guilherme Rossi Assis-Mendonça; André Fattori; Rafael Malagoli Rocha; Gustavo Jacob Lourenço; Márcia Torresan Delamain; Suely Nonogaki; Vladmir Cláudio Cordeiro de Lima; Gisele Wally Braga Colleoni; Cármino Antonio de Souza; Fernando Augusto Soares; Carmen Silvia Passos Lima; José Vassallo
Journal:  BMC Cancer       Date:  2021-03-01       Impact factor: 4.430

4.  Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.

Authors:  Kang Le; Jing Sun; Hunain Khawaja; Maho Shibata; Sanjay B Maggirwar; Mitchell R Smith; Mamta Gupta
Journal:  Blood Adv       Date:  2021-07-27

5.  BTK Promotes Atherosclerosis by Regulating Oxidative Stress, Mitochondrial Injury, and ER Stress of Macrophages.

Authors:  Junxiong Qiu; Yuan Fu; Zhiteng Chen; Lisui Zhang; Ling Li; Diefei Liang; Feng Wei; Zhuzhi Wen; Yajing Wang; Shi Liang
Journal:  Oxid Med Cell Longev       Date:  2021-05-27       Impact factor: 6.543

6.  Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.

Authors:  Laia Sadeghi; Gustav Arvidsson; Magali Merrien; Agata M Wasik; André Görgens; C I Edvard Smith; Birgitta Sander; Anthony P Wright
Journal:  Cancers (Basel)       Date:  2020-05-02       Impact factor: 6.639

Review 7.  Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies.

Authors:  Amy J Petty; Yiping Yang
Journal:  Cells       Date:  2019-11-27       Impact factor: 7.666

8.  CSF-1R inhibition disrupts the dialog between leukaemia cells and macrophages and delays leukaemia progression.

Authors:  Kun Li; Wenfu Xu; Ke Lu; Yuxi Wen; Tianqing Xin; Yaqing Shen; Xueyan Lv; Shimin Hu; Runming Jin; Xiaoyan Wu
Journal:  J Cell Mol Med       Date:  2020-10-10       Impact factor: 5.295

9.  Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Authors:  Jean-Pascal Machiels; Carlos Gomez-Roca; Jean-Marie Michot; Dmitriy Zamarin; Tara Mitchell; Gaetan Catala; Lauriane Eberst; Wolfgang Jacob; Anna-Maria Jegg; Michael A Cannarile; Carl Watson; Galina Babitzki; Konstanty Korski; Irina Klaman; Priscila Teixeira; Sabine Hoves; Carola Ries; Georgina Meneses-Lorente; Francesca Michielin; Randolph Christen; Dominik Rüttinger; Martin Weisser; Jean-Pierre Delord; Philippe Cassier
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

10.  TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma.

Authors:  Jiawei Rao; Xukun Wu; Xiaozhuan Zhou; Ronghai Deng; Yi Ma
Journal:  Front Genet       Date:  2020-10-14       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.